Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
Volume 0.06M
Average 0.44M
ENLV Other Financing Activities
Financing cash flows not reported separately.
Enlivex Therapeutics Ltd.NASDAQ: ENLV
Other Financing Activities · Q4 FY2025 · quarter ended Dec 2025
Other financing activities outflow shrinks to $0
Q4 FY2025 other financing activities was $0, compared with $2K a year earlier. Trailing-twelve-month other financing activities was -$24.23K.
Context
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$6.06K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 2K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 7.81M | — |
Other Financing Activities vs competitors
How ENLV compares with its peers on the latest reported figures
- ENLV's LTM Dec 2025 other financing activities of $24.23K is the smallest of the 2 companies compared; the peer median is $5.19M.
- Its year-over-year change of -157.0% is the lowest of 2, against a peer median of +2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NRXSNeurAxis, Inc. | LTM Mar 2026 | $5.19M | +2.7% | -6.3% | 121.3% |
| LTM Dec 2025 | $24.23K | -157.0% | — | — | |
| Peer median (excluding ENLV) | $5.19M | +2.7% | -6.3% | 121.3% | |
Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.24B |
| Depreciation & Amortization | 546K | 777K | 835K | 545K | 332K |
| Deferred Income Tax | (5.59M) | 0 | 0 | 0 | 382.65M |
| Stock-Based Compensation | 2.91M | 2.71M | 1.95M | 2.07M | 1.78M |
| Change in Working Capital | (1.36M) | 804K | (1.82M) | (1.22M) | 815K |
| Accounts Receivables | (1.25M) | 278K | 608K | 433K | (3.05M) |
| Inventory | 1.25M | (278K) | 0 | 0 | 0 |
| Accounts Payables | 442K | 1.17M | (1.12M) | (16K) | 3M |
| Other Working Capital | (1.8M) | (364K) | (1.31M) | (1.64M) | 869K |
| Other Non-Cash Items | 413K | 2.81M | 4.58M | 614K | (1.63B) |
| Operating Cash Flow | (17.54M) | (23.95M) | (23.52M) | (13.01M) | (10.42M) |
| Capital Expenditures | (1.63M) | (8.12M) | (236K) | (103K) | (68K) |
| Acquisitions (Net) | (20.03M) | (9.71M) | 0 | 0 | 1.38M |
| Purchases of Investments | (104.42M) | (1.61M) | (26.17M) | (32.37M) | (24.5M) |
| Sales of Investments | 67.63M | 72.25M | 301K | 39.24M | 41.37M |
| Other Investing Activities | 20.03M | 9.71M | 133K | 2.29M | 0 |
| Investing Cash Flow | (38.41M) | 62.52M | (25.97M) | 9.06M | (1.32M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.17M | 150K | 360K | 6.45M | 10.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.81M | 0 | 0 | 2K | 0 |
| Financing Cash Flow | 60.98M | 150K | 360K | 6.45M | 10.38M |
| Effect of Forex Changes | (408K) | (91K) | 0 | 0 | (49K) |
| Net Change in Cash | 4.62M | 38.72M | (49.13M) | 2.51M | (1.41M) |
| Free Cash Flow | (19.17M) | (32.08M) | (23.76M) | (13.11M) | (10.48M) |
Enlivex Therapeutics Ltd.
NASDAQ:ENLV
Intrinsic Alpha fair value
Locked
Current Price
$4.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.